Press Release

CURE Pharmaceutical Appoints Chief Business Officer

Jonathan Berlent Appointed to Newly Created Role

OXNARD, Calif., June 16, 2020 — CURE Pharmaceutical, (OTC: CURR), an innovative drug delivery and development company, today named Jonathan Berlent, 51, to the newly created position of Chief Business Officer. Mr. Berlent will be responsible for corporate strategy, sourcing and executing business development opportunities and will serve as a member of the company’s Executive Management Committee. He will report to Rob Davidson, CURE Pharmaceutical’s Chief Executive Officer.

“Jonathan’s extensive healthcare experience and industry insights are a welcome addition to CURE’s leadership team. In particular, his experience developing growth strategies will be critically important as we continue to expand our pipeline and strategic initiatives through business development,” said Mr. Davidson. “Appointing Jonathan to this newly created chief business officer role, heightens our focus on leveraging our platform technologies and cGMP facilities and expanding our commercial footprint in support of CURE’s long-term growth.”

Mr. Berlent is an accomplished business growth executive with more than 25 years of private and public company experience focused on strategic partnerships and building businesses seeking to own end-to-end market verticals. He has led successful strategic business initiatives across the pharmaceutical, healthcare, life sciences and health & wellness industries, with particular focus on CBD and cannabis, as well as diseases of the central nervous system, or CNS.

Among his previous roles, Mr. Berlent was managing director at Red Team Associates, a life science consultancy where he led business development, expansion and commercialization projects for leading life science companies. He served as chief operating officer of Tagleaf, an early stage, SaaS technology platform for the cannabis, food, pharma and agricultural analytical testing market and was interim chief executive officer at Trulee Health LLC. He has also held senior positions at Interpharm Holdings, Granules USA and Tris Pharma.

Mr. Berlent earned a bachelor’s degree in Economics from the University of Michigan and a Master’s in Business Administration from the New York University Stern School of Business with a concentration in Finance and Management.

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and patient experience through its proprietary drug forms and delivery systems.

CURE has an FDA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform which includes CUREfilm®, one of the most advanced oral thin films on the market today; CUREpods™ a novel chewable delivery system, and other more traditional dose forms that use advanced encapsulation technology. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients.

CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets.

More CURE News